The general opinion of the interviewed is that the new Regulation will strongly affect the trial management regardless of their type and phase, and the fulfillment of the imposed requirements represents an opportunity that Italy should not miss to increase its attractiveness to the pharmaceutical market.
Introduction
The European Clinical Trials Directive 2001/20/CE (ECTD) introduced in 2001 was the first effort to simplify and harmonize the regulation and conduction of Clinical Trials (CTs) across the European Union (EU).
ECTD introduced Good Clinical Practice (GCP) as a legal requirement for clinical research (CR), adding rigorous rules on ethics and safety for trial participants [1] .
Although this was a revolutionary approach, the ECTD failed in its aim as it was not binding. Each Member State (MS) was free to conform autonomously to the ECTD guidelines, resulting in divergent decisions of the local competent authorities.
Each MS adopted an individual submission method, with different timelines, obliging the sponsors to proceed with multiple different applications in each MS and, in some cases, in each center [2, 3] .
This resulted in increased bureaucracy, a lengthening in approval times and site activation (þ90%, average time 152 days), higher management costs (þ90% for no profit studies). Moreover, the obligation to take out trial insurance cover, led to an uncontrolled growth of expenses (up to þ800%), hardly affordable for independent research [3] [4] [5] .
Thus, the EU has become less attractive for the pharmaceutical market, with a significant reduction in the number of promoted CTs [6] [7] [8] [9] .
Due to its tradition of muddled bureaucracy, a multitude of Ethics Committees (ECs) and the lack of public funds for CR, Italy has been especially affected by these situation [5, 10] and recorded a reduction of 21% of activated CTs from 2008 to 2012 [11] .
In this scenario, the EU promoted two public consultations among all stakeholders to collect suggestions to replace ECTD. A first proposal was formalized on July 2012 [12] and the 'Regulation (EU) N.536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use' (ECTR) was finally adopted on 16 April 2014 [13] .
The ECTR aims to accelerate the application process by simplifying and harmonizing the administrative requirements for multicenter CTs across the EU and it is immediately applicable in all MS, without a need for transposition into the individual legislation [14] .
A single electronic application dossier, submitted through the EU portal provided by the European Medicine Agency (EMA) is its most innovative feature. CTs assessment will occur in a twostep process: the first, for evaluating the scientific rational, will be performed by a Reporting Member State (RMS) chosen by the sponsor, and will be binding on all MS; the second, conducted at a national level by each MS, will evaluate local and ethical aspects. ECTR provides an accurate time schedule for every step and provides for sanctions for non-compliant MS.
This coordinated approach will lead to a decision that applies to all MS, replacing single national approvals [8] .
Other important changes introduced include the concept of 'risk based CTs', with the definition of low intervention trial, the possibility of co-sponsorship, the protection of vulnerable populations, the definition of 'CTs in emergency situations' [7, 15, 16] . Increased transparency should be reached by the mandatory requirement of publishing the CT results, including negative findings.
The main differences between the ECTD and the ECTR are summarized in supplementary Appendix S1, available at Annals of Oncology online.
The ECTR was supposed to become effective on May 2016 [13] .To date, however, it is not active and forecasts indicate that it will not be implemented before late 2018 [17] .
Over the last year, ECTR has been the object of several Italian workshops, that highlighted some doubts on how quickly and efficiently its requirements will be met. To investigate the perception and knowledge of Italian's professionals involved in CTs about the upcoming changes, two separate online surveys, addressed to Italian Clinical Research Coordinators (CRCs) and Clinical investigators (CIs), respectively, were conducted.
Methods

Survey design
The survey was created with a Google web-based platform.
About 10 CRCs and 10 CIs were interviewed with two preliminary questionnaires and the results were used to design the final questionnaires, which consisted of 17 Italian multiple-choice items specifically addressed to CRCs and CIs. The survey explored four main domains: ECTR knowledge and training; key changes of the ECTR; impact on no-profit CTs; sites ability to fulfill the requirements.
The English version of the surveys is reported in supplementary Appendices S2 and S3, available at Annals of Oncology online.
Sampling method
Between April and June 2015, 190 CRCs from 'Gruppo Italiano Data Manager' (GIDM) and 80 Italian CIs from the main hospitals, networking and scientific societies involved in CR were interviewed .
The participants were recruited via email with an invitation to complete a freely accessible web survey. All data were anonymous and participation was strictly voluntary. Each survey took 10 min and the link was active for 10 days.
Data analysis
Given the descriptive nature of the surveys, we did not formally estimate a required sample size. In order to complete data analysis, we decided to obtain at least 50% of completed questionnaires from each group.
Data were analyzed on July 2015.
Results
CRCs questionnaire
Responses were received form 112 CRCs (58.9% of the sample). About 80.4% were aware of the new ECTR through multiple sources: participation in courses/workshops (48.2%), internet research (33%), personal reading (33%), networking (15.2%) and other sources (15.2%) (multiple choices allowed).
Most CRCs who claimed they had not been informed or were unaware of the ECTR, 95.9% would become aware through specific courses (97.5%) and personal reading (60.7%; multiple choice answers were allowed) while few (2.7%) would like to be informed although they believe that this is not mandatory for their work.
All respondents felt the need to transfer the ECTR information to their CIs; 65.2% believes that site staff are not yet fully aware of changes and 26.2% feels that CIs do not perceive the practical ECTR implications in the authorization process.
Indeed, 92% deems that the institutional channels have not provided adequate training and 88.4% believes that Hospital Management failed to apply or make the required changes compliant with ECTR. Furthermore, 46.4% has the feeling that only few ECs are already prepared or possess the resources to deal with changes.
Regarding the three most innovative aspects introduced by new Regulations, are identified in the centralization of authorization (74.2%), the single European web-portal (71%) and the new approval timing (44.1%) (Figure 1 ).
48.4% hold that ECTR will strongly affect both profit and noprofit studies and that it will facilitate CTs management (51.6%).
The survey highlights that some topics have not been adequately described in the ECTR, such as the involvement of ECs in the authorization process (41.4%), the new indications about insurances (22.9%) or the centralization of application procedure (22.9%) ( Figure 2) .
Finally, the majority of CRCs (71.4%) admits to not yet having a definite opinion about the new Regulation despite the general belief (85.7%) that it will have a direct impact on their work. T i m e l i n e s T h e s i n g l e E u r o p e a n w e b P o r t a l T h e n e w t r a n s p a r e n c y 
CIs questionnaire
A total of 50 responses (62.5%) were obtained from CIs almost all of whom are oncologist with a prevalence of onco-hematologist (16%), gastrointestinal (12%) and urogenital oncologists (10%) (Figure 3 ). The majority (64%) stated some knowledge of the ECTR, but felt they were to be inadequately informed, while 24% are not aware of the new regulation and only 12% stated they were fully aware. However, all the CIs who are not informed about ECTR, stated that an understanding of the Regulation is essential for carrying out CTs .
About half of CIs (54%) is aware of the need to provide, from the early phase of submission process, a written declaration that certifies the adequacy of the facilities and the presence of suitable personnel.
As far as the procedural changes, are concerned, 74% of the Investigators hold that Italy would only be able to fully adopt them after an initial period of transition. Only 10% believes that the new electronic and English-based submission procedures, will require Information Technology and English language skills which are not yet widespread among operators. The remaining 16% considers Italy already fully capable to implement the new rulings.
The coordinated evaluation procedure, which is no longer obtained by the individual participating center but with an approval issued by the MS, is seen as positive by the majority (74%) of respondents as it would lead to a streamlining of procedures.
About 88% of respondents also strongly agree with the identification of a RMS for the first evaluation phase, and consider the activity of each MS repeating an identical procedure as being redundant. However, 57% of them have some concerns about the criteria that will be used for the choice of the RMS .
As regards the second phase of the evaluation procedure, composed by Part I related to general study criteria, and by Part II related to the ethics and local feasibility, very few respondents (14%) consider this approach as undesirable, while many see it as appropriate (40%) but are concerned that this multistep procedure may result in long delays (Figure 4) . Almost all (90%) hope that the new EU procedure will shorten time for study approval and believe that the average of 106 days imposed by ECTR are a reasonable waiting time.
Those who will be appointed to make evaluation should be represented by a heterogeneous group, as it is for the existing ECs. Members of this group could be chosen by the Italian Competent Authority (Agenzia Italiana del Farmaco, AIFA) as a result of self-applications (44%), or from a direct call (10%). Alternatively, the evaluating staff could consist of a permanent core group from AIFA and members who can be involve, on demand, according to specific trial characteristics (46%).
Regarding the role of ECs, the majority (64%) agrees with the use of a single Committee, supervised by AIFA; 22% of them stated that the local EC should no longer be involved, while 14% stated that all existing ECs should be maintained to ensure a plurality of ethical opinions and advices.
Most participants (86%) are favorable of the obligation, for profit and non-profit CTs, to publish all results, as per the new transparency standards to be applied on CR. The remaining 14% believes that this obligation should only be applied to studies promoted by pharmaceutical companies. Less homogeneous are the opinions about the obligation of publishing a summary of the study results which a layperson can understand. Few respondents (2%) disagree, stating that patients would not be able to understand fully the report and its contents; 22% disagrees because of the concern that personal interpretation of data by nonspecialists might be dangerous; 38% affirmed that it would mainly depend on the type of information reported, while a further 38% agree with this obligation without any restriction.
The survey highlighted conflicting opinions about the possibility of a co-sponsored study. About 68% stated this would improve 100 % G a s t r o i n t e s t i n a l c a n c e r s R a r e c a n c e r s B r e a s t c a n c e r s G y n e c o l o g i c a l c a n c e r s U r o g e n i t a l c a n c e r s H e m a t o l o g i c a l c a n c e r s research, while 18% do not think that this would successfully affect a study. About 14% believes that co-sponsorship has be disadvantage due to possible conflicts of interests and a lack of clarity on shared responsibilities among individual sponsors. Several respondents expressed perplexities concerning the issue of insurances cover not be provided by the Sponsor for low risk level studies, but being the responsibility of single MS. Over half (54%) believes that the obligation to guarantee CT insurance should be always provided by the Sponsor, and 20% are worried about the possibility that Italy would not have enough funds to meet compensation payments.
Overall, the majority (74%) believes that their facilities and staff already meet the Regulation requirements, while only a few stated that these requirements are only partially met (8%) or that the need for this qualification is related to specific CT requirements (18%).
About 50% of CIs stated that the new ruling will promote independent CR, although some (8%) are concerned that this might affect Italy. About 42% believe that the ECTR will only affect trials sponsored by pharmaceutical companies.
Discussion
The new ECTR has very ambitious goals: to push Europe to be more competitive in CTs scenario, to improve transparency, to create a simplified regulatory system and to increase public trust [8, 14] .
Focusing on the Italian scene, Italy is Europe's third largest bio-pharmaceutical market [18] : investigators excel in terms of health care, scientific publications and medical society leadership [19] , with 8139 CTs carried out from 2000 to 2012 [11] .
Nevertheless CR in Italy was strongly affected by the consequences of ECTD. According to EudraCT (EU clinical trial database), Italy has decreased its share of total European trials, with a fall of CTs registered in the US National Institute of Health's (NIH) database from 18.5% in 2008 to 17.7% in 2012 [19, 20] . The results of a survey distributed to pharmaceutical companies, medical device manufacturers, Clinical Research Organizations and academic Clinical Trial Units (CTUs) by the SAT-EU Study Group show that Italy ranks last of nine European countries in the number of NIH-registered trials per capita [5, 20] .
The reasons for this lack of attractiveness have been identified in bureaucratic procedures that penalize the high scientific level and research standards of the Italian Investigators [21] . This is more evident for independent research that usually has longer times for activation and can only count on limited financial resources and on professionals who do not enjoy permanent employment contracts [22] [23] [24] .
According to data collected by the SAT-EU Study Group, the implementation of streamlined legislation governing CTs, a reduction in the number of ECs, a standardization of contracts and the creation of qualified CTUs will reverse this trend and will improve the status of CR in Italy [10] .
For these reasons, we decided to investigate how Italy is preparing to implement and apply the changes introduced by the new ECTR and to evaluate its impact on researchers and CRCs.
CRCs are more informed about ECTR with the 80.4% of them being aware of the innovations that will be introduced, only 12% deem themselves fully informed about it and 24% are not even aware of the incoming new Regulation. In addition, many CRCs (26.2%) believe that the CT staff of their sites do not yet have the perception of the practical implications introduced in the authorization process. The common feeling (confirmed by 92% of CRCs) is that institutional channels and the management of Hospitals/Institutes are doing too little to inform clinical researchers about the ECTR and have not yet implemented any plans in order to be ready to meet the requirements and. information on this topic still relies only on personal initiative.
According to CRCs, the most functional innovations introduced by the ECTR are the centralization of procedures, the building of a European Portal and the new timings for approval. This view appears to be shared by the CIs who are mainly favorable of a centralization of the evaluation process, once the criteria for choosing the RMS has been clarified.
However, opinions on the role of EC are uniform: the majority of the CIs consider the multiplicity of Italian ECs as unnecessary, and calls for the return to a single national EC supported by AIFA, to ensure a speeding up of procedures. Unfortunately, the Regulation is unclear and, to date, AIFA has not expressed its intentions.
Furthermore, ECTR does not clearly define the source of funds for compensation for case of low-intervention trials that do not require study specific insurance cover. More than half of CIs believe that insurance should always be provided by the sponsor and 20% are worried about the possibility that Italy might not have adequate resources in case of compensation to study participants. Regarding the new transparency policy, almost every participant agrees on the obligation of publishing data regardless of the profit or no-profit nature of the study. However, more concerns were expressed about the divulgation of understandable summaries for laypeople. Researchers agree on their right to be informed, but are doubtful about the real understanding of results and on how this information could affect the relationship of trust between physician and patient.
According to the majority of CRCs, ECTR will have important consequences for both Investigator initiated CT and profit trials and it will facilitate running the trials.
The general opinion, especially that of CRCs, was that Italy is not yet ready to accommodate the changes. According to respondents, a tradition of slow bureaucracy, limited English language skills and the low susceptibility to changes, will have a negative effect on the utmost speed and efficiency required by the Regulation.
Indeed, Europe in general has proven to be slower than had been expected. The delay of the European Commission in finalizing the EU portal will lead to a full application of the ECTRT being postponed, and finalization is now scheduled for the end of 2018 [17] .
Limitation
Consistent with voluntary surveys, we only analyzed responses of CRCs and CIs interested in replying, and therefore we cannot exclude the fact that other points of view may have emerged. Moreover, we have to choose only two categories of professionals involved in CR.
Lastly, while we took due care in designing a survey focused on the major innovations of ECTR other potentially important aspects may have been missed.
Conclusions
The new European Regulation represents a turning point for the carrying out of CTs in the EU and its ambitious goals will require a rigorous methodology and an increased quality. The obvious question is: 'Is Italy really ready to face this challenge?'. The answer from CRCs is pessimistic. According to them, institutional management teams have failed to apply or provide the required and expected changes and only a few states that ECs already have the capacity or resources to deal with implementation.
The Investigator's position is, on the contrary, more optimistic. Most CIs thinks that after an initial period of transition, Italy will be capable to adopt fully the requirements.
What seems obvious is that Italy should speed up and implement the required procedural changes in order to keep its prestigious role on the international scene for both pharmaceutical companies and academia. This transition period will be critical especially for the independent research which could draw the utmost benefit from a rigorous model but will also have to deal with limited economic and dedicated personnel resources.
If these requirements are not satisfied, Italy will miss a chance to be competitive within the EU and will not able to guarantee access to the most advanced and innovative therapeutic options for Italian patients.
